Cargando…

Gut Microbiota and B Cell Receptor (BCR) Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Is Biodiversity Correlated with Clinical Response or Immune-Related Adverse Event Occurrence? A Cross-Sectional Study

Several studies have strengthened the link between the gut microbiota (GM) and the response to immunotherapy in patients with tumors, highlighting the potential role of GM as a biomarker of response. Targeted therapies including B-cell receptor (BCR) inhibitors (BCRi) represent the newest approach t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zuccaro, Valentina, Petazzoni, Greta, Mileto, Irene, Corbella, Marta, Asperges, Erika, Sacchi, Paolo, Rattotti, Sara, Varettoni, Marzia, Defrancesco, Irene, Cambieri, Patrizia, Baldanti, Fausto, Arcaini, Luca, Bruno, Raffaele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223513/
https://www.ncbi.nlm.nih.gov/pubmed/37317279
http://dx.doi.org/10.3390/microorganisms11051305
_version_ 1785049960100659200
author Zuccaro, Valentina
Petazzoni, Greta
Mileto, Irene
Corbella, Marta
Asperges, Erika
Sacchi, Paolo
Rattotti, Sara
Varettoni, Marzia
Defrancesco, Irene
Cambieri, Patrizia
Baldanti, Fausto
Arcaini, Luca
Bruno, Raffaele
author_facet Zuccaro, Valentina
Petazzoni, Greta
Mileto, Irene
Corbella, Marta
Asperges, Erika
Sacchi, Paolo
Rattotti, Sara
Varettoni, Marzia
Defrancesco, Irene
Cambieri, Patrizia
Baldanti, Fausto
Arcaini, Luca
Bruno, Raffaele
author_sort Zuccaro, Valentina
collection PubMed
description Several studies have strengthened the link between the gut microbiota (GM) and the response to immunotherapy in patients with tumors, highlighting the potential role of GM as a biomarker of response. Targeted therapies including B-cell receptor (BCR) inhibitors (BCRi) represent the newest approach to the treatment of chronic lymphocytic leukemia (CLL); however, not all patients achieve a satisfactory response, and immune-related adverse events (irAEs) can also impact the efficacy. The aim of the study was to compare GM biodiversity in patients with CLL, treated with BCRi for at least 12 months. Twelve patients were enrolled: 10 patients in the responder group (R) and 2 patients in the non-responder group (NR). We identified seven patients (58.3%) who experienced adverse reactions (AE). Although we did not observe a significant difference across the study population in terms of relative abundance and alpha and beta diversity, we found a differing distribution of bacterial taxa between the analyzed groups. We noted a higher level of the class Bacteroidia and the order Bacteroidales in the R group, and an inversion in the Firmicutes and Bacteroidetes ratio in the AE group. No prior studies have focused on linking GM and response to BCRi in these patients. Although the analyses are preliminary, they provide suggestions to guide future research.
format Online
Article
Text
id pubmed-10223513
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102235132023-05-28 Gut Microbiota and B Cell Receptor (BCR) Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Is Biodiversity Correlated with Clinical Response or Immune-Related Adverse Event Occurrence? A Cross-Sectional Study Zuccaro, Valentina Petazzoni, Greta Mileto, Irene Corbella, Marta Asperges, Erika Sacchi, Paolo Rattotti, Sara Varettoni, Marzia Defrancesco, Irene Cambieri, Patrizia Baldanti, Fausto Arcaini, Luca Bruno, Raffaele Microorganisms Article Several studies have strengthened the link between the gut microbiota (GM) and the response to immunotherapy in patients with tumors, highlighting the potential role of GM as a biomarker of response. Targeted therapies including B-cell receptor (BCR) inhibitors (BCRi) represent the newest approach to the treatment of chronic lymphocytic leukemia (CLL); however, not all patients achieve a satisfactory response, and immune-related adverse events (irAEs) can also impact the efficacy. The aim of the study was to compare GM biodiversity in patients with CLL, treated with BCRi for at least 12 months. Twelve patients were enrolled: 10 patients in the responder group (R) and 2 patients in the non-responder group (NR). We identified seven patients (58.3%) who experienced adverse reactions (AE). Although we did not observe a significant difference across the study population in terms of relative abundance and alpha and beta diversity, we found a differing distribution of bacterial taxa between the analyzed groups. We noted a higher level of the class Bacteroidia and the order Bacteroidales in the R group, and an inversion in the Firmicutes and Bacteroidetes ratio in the AE group. No prior studies have focused on linking GM and response to BCRi in these patients. Although the analyses are preliminary, they provide suggestions to guide future research. MDPI 2023-05-17 /pmc/articles/PMC10223513/ /pubmed/37317279 http://dx.doi.org/10.3390/microorganisms11051305 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zuccaro, Valentina
Petazzoni, Greta
Mileto, Irene
Corbella, Marta
Asperges, Erika
Sacchi, Paolo
Rattotti, Sara
Varettoni, Marzia
Defrancesco, Irene
Cambieri, Patrizia
Baldanti, Fausto
Arcaini, Luca
Bruno, Raffaele
Gut Microbiota and B Cell Receptor (BCR) Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Is Biodiversity Correlated with Clinical Response or Immune-Related Adverse Event Occurrence? A Cross-Sectional Study
title Gut Microbiota and B Cell Receptor (BCR) Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Is Biodiversity Correlated with Clinical Response or Immune-Related Adverse Event Occurrence? A Cross-Sectional Study
title_full Gut Microbiota and B Cell Receptor (BCR) Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Is Biodiversity Correlated with Clinical Response or Immune-Related Adverse Event Occurrence? A Cross-Sectional Study
title_fullStr Gut Microbiota and B Cell Receptor (BCR) Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Is Biodiversity Correlated with Clinical Response or Immune-Related Adverse Event Occurrence? A Cross-Sectional Study
title_full_unstemmed Gut Microbiota and B Cell Receptor (BCR) Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Is Biodiversity Correlated with Clinical Response or Immune-Related Adverse Event Occurrence? A Cross-Sectional Study
title_short Gut Microbiota and B Cell Receptor (BCR) Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Is Biodiversity Correlated with Clinical Response or Immune-Related Adverse Event Occurrence? A Cross-Sectional Study
title_sort gut microbiota and b cell receptor (bcr) inhibitors for the treatment of chronic lymphocytic leukemia: is biodiversity correlated with clinical response or immune-related adverse event occurrence? a cross-sectional study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223513/
https://www.ncbi.nlm.nih.gov/pubmed/37317279
http://dx.doi.org/10.3390/microorganisms11051305
work_keys_str_mv AT zuccarovalentina gutmicrobiotaandbcellreceptorbcrinhibitorsforthetreatmentofchroniclymphocyticleukemiaisbiodiversitycorrelatedwithclinicalresponseorimmunerelatedadverseeventoccurrenceacrosssectionalstudy
AT petazzonigreta gutmicrobiotaandbcellreceptorbcrinhibitorsforthetreatmentofchroniclymphocyticleukemiaisbiodiversitycorrelatedwithclinicalresponseorimmunerelatedadverseeventoccurrenceacrosssectionalstudy
AT miletoirene gutmicrobiotaandbcellreceptorbcrinhibitorsforthetreatmentofchroniclymphocyticleukemiaisbiodiversitycorrelatedwithclinicalresponseorimmunerelatedadverseeventoccurrenceacrosssectionalstudy
AT corbellamarta gutmicrobiotaandbcellreceptorbcrinhibitorsforthetreatmentofchroniclymphocyticleukemiaisbiodiversitycorrelatedwithclinicalresponseorimmunerelatedadverseeventoccurrenceacrosssectionalstudy
AT aspergeserika gutmicrobiotaandbcellreceptorbcrinhibitorsforthetreatmentofchroniclymphocyticleukemiaisbiodiversitycorrelatedwithclinicalresponseorimmunerelatedadverseeventoccurrenceacrosssectionalstudy
AT sacchipaolo gutmicrobiotaandbcellreceptorbcrinhibitorsforthetreatmentofchroniclymphocyticleukemiaisbiodiversitycorrelatedwithclinicalresponseorimmunerelatedadverseeventoccurrenceacrosssectionalstudy
AT rattottisara gutmicrobiotaandbcellreceptorbcrinhibitorsforthetreatmentofchroniclymphocyticleukemiaisbiodiversitycorrelatedwithclinicalresponseorimmunerelatedadverseeventoccurrenceacrosssectionalstudy
AT varettonimarzia gutmicrobiotaandbcellreceptorbcrinhibitorsforthetreatmentofchroniclymphocyticleukemiaisbiodiversitycorrelatedwithclinicalresponseorimmunerelatedadverseeventoccurrenceacrosssectionalstudy
AT defrancescoirene gutmicrobiotaandbcellreceptorbcrinhibitorsforthetreatmentofchroniclymphocyticleukemiaisbiodiversitycorrelatedwithclinicalresponseorimmunerelatedadverseeventoccurrenceacrosssectionalstudy
AT cambieripatrizia gutmicrobiotaandbcellreceptorbcrinhibitorsforthetreatmentofchroniclymphocyticleukemiaisbiodiversitycorrelatedwithclinicalresponseorimmunerelatedadverseeventoccurrenceacrosssectionalstudy
AT baldantifausto gutmicrobiotaandbcellreceptorbcrinhibitorsforthetreatmentofchroniclymphocyticleukemiaisbiodiversitycorrelatedwithclinicalresponseorimmunerelatedadverseeventoccurrenceacrosssectionalstudy
AT arcainiluca gutmicrobiotaandbcellreceptorbcrinhibitorsforthetreatmentofchroniclymphocyticleukemiaisbiodiversitycorrelatedwithclinicalresponseorimmunerelatedadverseeventoccurrenceacrosssectionalstudy
AT brunoraffaele gutmicrobiotaandbcellreceptorbcrinhibitorsforthetreatmentofchroniclymphocyticleukemiaisbiodiversitycorrelatedwithclinicalresponseorimmunerelatedadverseeventoccurrenceacrosssectionalstudy